Why haven’t biosimilars gained ground in the U.S.?
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
Two years after the first biosimilar approval in the U.S., biosimilars have yet to match sales forecasts. What is their path forward?
FDA develops resources about biosimilars for HCPs; Biogen negotiates royalties for experimental Alzheimer’s drug; GSK Q3 sales driven by HIV, respiratory drugs
Biosimilars could save $54 billion in next decade; White House requests drug-pricing task force; FDA approves GSK shingle vaccine
Pfizer sues J&J over Remicade contracts; drugmakers trim sales forces for rare-disease drugs; Roche’s oncology business under siege from biosimilars
Only three of the seven FDA-approved biosimilars are available for sale; Teva to sell off women’s health portfolio; the FDA approves GSK’s COPD combo
The FDA approves first cancer biosimilar; it also approves Bayer’s new lymphoma drug; clinical-trial participation for gynecological cancer drops
Gilead to acquire Kite; the FDA issues fewest number of warning letters since 2008; the regulator approves BI’s Humira biosimilar
Google surveys for depression; patients with diabetes that adhere to their regimen had fewer ER visits; Biogen, Samsung scores Humira biosimilar approval in EU
Pfizer accuses J&J of limiting biosimilar uptake; Trump again criticizes high drug prices; WebMD to reposition site to help consumers manage their health
Teva gets FDA approval for Truvada generic; the FDA rejects Coherus’ Neulasta biosimilar; only 17% of Americans find health industries to be innovative